# Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

> **NCT04956289** · PHASE2 · COMPLETED · sponsor: **NS Pharma, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Viltolarsen

## Key facts

- **NCT ID:** NCT04956289
- **Lead sponsor:** NS Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-07-13
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956289, "Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04956289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*